Request Demo
Last update 29 Mar 2025
TQB-2618
Last update 29 Mar 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms TQB 2618, TQB2618 |
Target |
Action inhibitors |
Mechanism TIM3 inhibitors(Hepatitis A virus cellular receptor 2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
19
Clinical Trials associated with TQB-2618CTR20240145
评估TQB2618注射液联合派安普利单抗注射液与盐酸安罗替尼胶囊一线治疗晚期肝细胞癌的有效性和安全性Ib期临床研究
[Translation] Phase Ib clinical study to evaluate the efficacy and safety of TQB2618 injection combined with penpulimab injection and anlotinib hydrochloride capsules as first-line treatment for advanced hepatocellular carcinoma
NCT06010901
A Phase Ib Clinical Study to Evaluate the Efficacy and Safety of of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
CTR20233217
评估 TQB2618 注射液单药及联合方案（派安普利单抗±安罗替尼）四线及后线治疗晚期结直肠癌的有效性和安全性 Ib 期临床研究
[Translation] Phase Ib clinical study to evaluate the efficacy and safety of TQB2618 injection alone and in combination with penpulimab ± anlotinib in the fourth-line and later-line treatment of advanced colorectal cancer
100 Clinical Results associated with TQB-2618
Login to view more data
100 Translational Medicine associated with TQB-2618
Login to view more data
100 Patents (Medical) associated with TQB-2618
Login to view more data
100 Deals associated with TQB-2618
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | China | 26 May 2023 | |
| Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | China | 23 May 2023 | |
| Squamous cell carcinoma, metastatic | Phase 2 | China | 23 May 2023 | |
| Nasopharyngeal Carcinoma | Phase 2 | China | 27 Oct 2022 | |
| Recurrent Lymphoma | Phase 2 | China | 09 Jun 2022 | |
| Refractory Lymphoma | Phase 2 | China | 09 Jun 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 28 Apr 2022 | |
| Squamous cell carcinoma of head and neck metastatic | Phase 1 | China | 14 Mar 2024 | |
| Colorectal Cancer | Phase 1 | China | 22 Dec 2023 | |
| Metastatic Colorectal Carcinoma | Phase 1 | China | 22 Dec 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 17 | sxvnopnwdm(wouuxulfrc) = eybcjjpdze bzthccihnj (dnyojhlmyx ) View more | Negative | 12 Dec 2024 | |||
WCLC2024 Manual  | Phase 1 | 93 | hmiswxzgmy(wkyxvzyyre) = pktdcuqwsk sdqgqzxswi (guxpgwznjw ) View more | Positive | 10 Sep 2024 | ||
hmiswxzgmy(wkyxvzyyre) = rnndbidsui sdqgqzxswi (guxpgwznjw ) View more | |||||||
NCT05400876 (EHA2024) Manual | Phase 1 | 21 | khbygaekkn(eujwzrgpdc) = 17 (81%) patients experienced treatment-related adverse events (TRAEs), 5 (23.8%) of whom experienced grade 3 or above TRAEs. The most frequent TRAEs (≥15%) were platelet count decreased (23.8%), anemia (23.8%), alanine aminotransferase increased (19%) and Aspartate aminotransferase increased (19%). The most common grade 3 or above TRAEs were anemia (9.5%) and white blood count decreased (9.5%). byzxhjawbk (almwntmevw ) View more | Positive | 14 May 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free